Format

Send to

Choose Destination
FASEB J. 2020 Jan;34(1):192-207. doi: 10.1096/fj.201901896RR. Epub 2019 Nov 20.

An antimicrobial molecule mitigates signs of sepsis in vivo and eradicates infections from lung tissue.

Author information

1
SetLance srl, Siena, Italy.
2
Department of Medical Biotechnology, University of Siena, Siena, Italy.
3
Department of Life Sciences and Biotechnology, University of Ferrara, Ferrara, Italy.
4
Fraunhofer Institute for Toxicology and Experimental Medicine (ITEM), Member of Fraunhofer international Consortium for Anti-Infective Research (iCAIR), Hannover, Germany.
5
Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
6
Microbiology and Virology Unit, Florence Careggi University Hospital, Florence, Italy.
7
Department of Life Sciences, University of Siena, Siena, Italy.

Abstract

The peptide sequence KKIRVRLSA was synthesized in a dimeric structure (SET-M33DIM) and evaluated as a candidate drug for infections due to multidrug-resistant (MDR) Gram-negative pathogens. SET-M33DIM showed significant antibacterial activity against MDR strains of Klebsiella pneumoniae, Acinetobacter baumannii, and Escherichia coli (Minimal Inhibitory Concentration [MICs], 1.5-11 µM), and less activity against Pseudomonas aeruginosa (MICs, 11-22 µM). It showed very low toxicity in vitro, ex vivo, and in vivo; in cytotoxicity tests, its EC50 was as much as 22 times better than that of SET-M33, a peptide with the same amino-acid sequence, but synthesized in tetra-branched form (638 vs 28 µM). In in vivo and ex vivo experiments, SET-M33DIM cleared P. aeruginosa infection, significantly reducing signs of sepsis in animals, and restoring cell viability in lung tissue after bacterial challenge. It also quelled inflammation triggered by LPS and live bacterial cells, inhibiting expression of inflammatory mediators in lung tissue, cultured macrophages, and bronchial cells from a cystic fibrosis patient.

KEYWORDS:

antibacterial agents; antibiotic resistance; antimicrobial peptides; drug development

PMID:
31914681
DOI:
10.1096/fj.201901896RR

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center